161 related articles for article (PubMed ID: 16152762)
1. Protection of mammalian cells from severe acute respiratory syndrome coronavirus infection by equine neutralizing antibody.
Wang X; Ni B; Du X; Zhao G; Gao W; Shi X; Zhang S; Zhang L; Wang D; Luo D; Xing L; Jiang H; Li W; Jiang M; Mao L; He Y; Xiao Y; Wu Y
Antivir Ther; 2005; 10(5):681-90. PubMed ID: 16152762
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of the safety, immunogenicity and pharmacokinetics of equine anti-SARS-CoV F(ab')(2) in macaque.
Xu Y; Jia Z; Zhou L; Wang L; Li J; Liang Y; Zhao T; Ni B; Wu Y
Int Immunopharmacol; 2007 Dec; 7(13):1834-40. PubMed ID: 17996696
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of infection caused by severe acute respiratory syndrome-associated coronavirus by equine neutralizing antibody in aged mice.
Zhou L; Ni B; Luo D; Zhao G; Jia Z; Zhang L; Lin Z; Wang L; Zhang S; Xing L; Li J; Liang Y; Shi X; Zhao T; Zhou L; Wu Y; Wang X
Int Immunopharmacol; 2007 Mar; 7(3):392-400. PubMed ID: 17276898
[TBL] [Abstract][Full Text] [Related]
4. Passive immunotherapy for influenza A H5N1 virus infection with equine hyperimmune globulin F(ab')2 in mice.
Lu J; Guo Z; Pan X; Wang G; Zhang D; Li Y; Tan B; Ouyang L; Yu X
Respir Res; 2006 Mar; 7(1):43. PubMed ID: 16553963
[TBL] [Abstract][Full Text] [Related]
5. Protection from infection with severe acute respiratory syndrome coronavirus in a Chinese hamster model by equine neutralizing F(ab')2.
Luo D; Ni B; Zhao G; Jia Z; Zhou L; Pacal M; Zhang L; Zhang S; Xing L; Lin Z; Wang L; Li J; Liang Y; Shi X; Zhao T; Zou L; Wu Y; Wang X
Viral Immunol; 2007 Sep; 20(3):495-502. PubMed ID: 17931120
[TBL] [Abstract][Full Text] [Related]
6. Preparation and development of equine hyperimmune globulin F(ab')2 against severe acute respiratory syndrome coronavirus.
Lu JH; Guo ZM; Han WY; Wang GL; Zhang DM; Wang YF; Sun SY; Yang QH; Zheng HY; Wong BL; Zhong NS
Acta Pharmacol Sin; 2005 Dec; 26(12):1479-84. PubMed ID: 16297347
[TBL] [Abstract][Full Text] [Related]
7. Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody.
Pinto D; Park YJ; Beltramello M; Walls AC; Tortorici MA; Bianchi S; Jaconi S; Culap K; Zatta F; De Marco A; Peter A; Guarino B; Spreafico R; Cameroni E; Case JB; Chen RE; Havenar-Daughton C; Snell G; Telenti A; Virgin HW; Lanzavecchia A; Diamond MS; Fink K; Veesler D; Corti D
Nature; 2020 Jul; 583(7815):290-295. PubMed ID: 32422645
[TBL] [Abstract][Full Text] [Related]
8. Human monoclonal antibody combination against SARS coronavirus: synergy and coverage of escape mutants.
ter Meulen J; van den Brink EN; Poon LL; Marissen WE; Leung CS; Cox F; Cheung CY; Bakker AQ; Bogaards JA; van Deventer E; Preiser W; Doerr HW; Chow VT; de Kruif J; Peiris JS; Goudsmit J
PLoS Med; 2006 Jul; 3(7):e237. PubMed ID: 16796401
[TBL] [Abstract][Full Text] [Related]
9. SARS patients-derived human recombinant antibodies to S and M proteins efficiently neutralize SARS-coronavirus infectivity.
Liang MF; Du RL; Liu JZ; Li C; Zhang QF; Han LL; Yu JS; Duan SM; Wang XF; Wu KX; Xiong ZH; Jin Q; Li DX
Biomed Environ Sci; 2005 Dec; 18(6):363-74. PubMed ID: 16544518
[TBL] [Abstract][Full Text] [Related]
10. Protection from infection with influenza A H7N9 virus in a mouse model by equine neutralizing F(ab')2.
Zhao Z; Fan C; Duan Y; Zhang L; Li M; Yang X; Li R; Yang P; Wang X
Int Immunopharmacol; 2014 Nov; 23(1):134-8. PubMed ID: 25192652
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of severe acute respiratory syndrome-associated coronavirus infection by equine neutralizing antibody in golden Syrian hamsters.
Zhao G; Ni B; Jiang H; Luo D; Pacal M; Zhou L; Zhang L; Xing L; Zhang L; Jia Z; Lin Z; Wang L; Li J; Liang Y; Shi X; Zhao T; Zhou L; Wu Y; Wang X
Viral Immunol; 2007; 20(1):197-205. PubMed ID: 17425434
[TBL] [Abstract][Full Text] [Related]
12. Contributions of the structural proteins of severe acute respiratory syndrome coronavirus to protective immunity.
Buchholz UJ; Bukreyev A; Yang L; Lamirande EW; Murphy BR; Subbarao K; Collins PL
Proc Natl Acad Sci U S A; 2004 Jun; 101(26):9804-9. PubMed ID: 15210961
[TBL] [Abstract][Full Text] [Related]
13. Assays for the assessment of neutralizing antibody activities against Severe Acute Respiratory Syndrome (SARS) associated coronavirus (SCV).
Wang S; Sakhatskyy P; Chou TH; Lu S
J Immunol Methods; 2005 Jun; 301(1-2):21-30. PubMed ID: 15894326
[TBL] [Abstract][Full Text] [Related]
14. Development and characterization of a severe acute respiratory syndrome-associated coronavirus-neutralizing human monoclonal antibody that provides effective immunoprophylaxis in mice.
Greenough TC; Babcock GJ; Roberts A; Hernandez HJ; Thomas WD; Coccia JA; Graziano RF; Srinivasan M; Lowy I; Finberg RW; Subbarao K; Vogel L; Somasundaran M; Luzuriaga K; Sullivan JL; Ambrosino DM
J Infect Dis; 2005 Feb; 191(4):507-14. PubMed ID: 15655773
[TBL] [Abstract][Full Text] [Related]
15. Comparative evaluation of two severe acute respiratory syndrome (SARS) vaccine candidates in mice challenged with SARS coronavirus.
See RH; Zakhartchouk AN; Petric M; Lawrence DJ; Mok CPY; Hogan RJ; Rowe T; Zitzow LA; Karunakaran KP; Hitt MM; Graham FL; Prevec L; Mahony JB; Sharon C; Auperin TC; Rini JM; Tingle AJ; Scheifele DW; Skowronski DM; Patrick DM; Voss TG; Babiuk LA; Gauldie J; Roper RL; Brunham RC; Finlay BB
J Gen Virol; 2006 Mar; 87(Pt 3):641-650. PubMed ID: 16476986
[TBL] [Abstract][Full Text] [Related]
16. Cross clade prophylactic and therapeutic efficacy of polyvalent equine immunoglobulin F(ab')2 against highly pathogenic avian influenza H5N1 in mice.
Zhao Z; Yan F; Chen Z; Luo D; Duan Y; Yang P; Li Z; Peng D; Liu X; Wang X
Int Immunopharmacol; 2011 Dec; 11(12):2000-6. PubMed ID: 21906698
[TBL] [Abstract][Full Text] [Related]
17. Passive immunotherapy for Middle East Respiratory Syndrome coronavirus infection with equine immunoglobulin or immunoglobulin fragments in a mouse model.
Zhao Y; Wang C; Qiu B; Li C; Wang H; Jin H; Gai W; Zheng X; Wang T; Sun W; Yan F; Gao Y; Wang Q; Yan J; Chen L; Perlman S; Zhong N; Zhao J; Yang S; Xia X
Antiviral Res; 2017 Jan; 137():125-130. PubMed ID: 27890674
[TBL] [Abstract][Full Text] [Related]
18. Immunogenicity and protective efficacy in monkeys of purified inactivated Vero-cell SARS vaccine.
Qin E; Shi H; Tang L; Wang C; Chang G; Ding Z; Zhao K; Wang J; Chen Z; Yu M; Si B; Liu J; Wu D; Cheng X; Yang B; Peng W; Meng Q; Liu B; Han W; Yin X; Duan H; Zhan D; Tian L; Li S; Wu J; Tan G; Li Y; Li Y; Liu Y; Liu H; Lv F; Zhang Y; Kong X; Fan B; Jiang T; Xu S; Wang X; Li C; Wu X; Deng Y; Zhao M; Zhu Q
Vaccine; 2006 Feb; 24(7):1028-34. PubMed ID: 16388880
[TBL] [Abstract][Full Text] [Related]
19. Equine immunoglobulin fragment F(ab')
Gupta D; Ahmed F; Tandel D; Parthasarathy H; Vedagiri D; Sah V; Krishna Mohan B; Khan RA; Kondiparthi C; Savari P; Jain S; Reddy S; Kumar JM; Khan N; Harshan KH
Clin Immunol; 2022 Apr; 237():108981. PubMed ID: 35306171
[TBL] [Abstract][Full Text] [Related]
20. Rapid discovery and optimization of therapeutic antibodies against emerging infectious diseases.
Rogers J; Schoepp RJ; Schröder O; Clements TL; Holland TF; Li JQ; Li J; Lewis LM; Dirmeier RP; Frey GJ; Tan X; Wong K; Woodnutt G; Keller M; Reed DS; Kimmel BE; Tozer EC
Protein Eng Des Sel; 2008 Aug; 21(8):495-505. PubMed ID: 18480090
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
